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http://www.biomedcentral.com/1471-230X/12/182RESEARCH ARTICLE Open AccessAdditional corpus biopsy enhances the detection
of Helicobacter pylori infection in a background of
gastritis with atrophy
Hung-Chieh Lan1,3, Tseng-Shing Chen1*, Anna Fen-Yau Li2, Full-Young Chang1 and Han-Chieh Lin1Abstract
Background: The best sites for biopsy-based tests to evaluate H. pylori infection in gastritis with atrophy are not
well known. This study aimed to evaluate the site and sensitivity of biopsy-based tests in terms of degree of
gastritis with atrophy.
Methods: One hundred and sixty-four (164) uninvestigated dyspepsia patients were enrolled. Biopsy-based tests
(i.e., culture, histology Giemsa stain and rapid urease test) and non-invasive tests (anti-H. pylori IgG) were performed.
The gold standard of H. pylori infection was defined according to previous criteria. The sensitivity, specificity,
positive predictive rate and negative predictive rate of biopsy-based tests at the gastric antrum and body were
calculated in terms of degree of gastritis with atrophy.
Results: The prevalence rate of H. pylori infection in the 164 patients was 63.4%. Gastritis with atrophy was
significantly higher at the antrum than at the body (76% vs. 31%; p<0.001). The sensitivity of biopsy-based test
decreased when the degree of gastritis with atrophy increased regardless of biopsy site (for normal, mild, moderate,
and severe gastritis with atrophy, the sensitivity of histology Giemsa stain was 100%, 100%, 88%, and 66%,
respectively, and 100%, 97%, 91%, and 66%, respectively, for rapid urease test). In moderate to severe antrum or
body gastritis with atrophy, additional corpus biopsy resulted in increased sensitivity to 16.67% compare to single
antrum biopsy.
Conclusions: In moderate to severe gastritis with atrophy, biopsy-based test should include the corpus for
avoiding false negative results.
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Helicobacter pylori (H. pylori) and gastritis with atrophy
are both risk factors for gastric cancer [1]. Around one-
third of infected patients are estimated to have gastritis
with atrophy [2] and the regression of these pre-
neoplasm lesions may occur after successful eradication
[3-5]. As such, H. pylori eradication in patients with
gastritis with atrophy is recommended by current guide-
lines [1,6,7].
Although eradication is essential for this group of
patients, the accurate identification of H. pylori against* Correspondence: tschen@vghtpe.gov.tw
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reproduction in any medium, provided the ora background of gastritis with atrophy remains difficult
[8]. False negative results occur even under more reliable
H. pylori diagnostic tests like histology Giemsa stain [9].
False negative status, or the so-called sampling error, may
result from patchy bacterial colonization through the
stomach and altered distribution because of gastritis with
atrophy and intestinal metaplasia. Thus, it is important to
set a recommended biopsy site.
The updated Sydney Classification had set the gold
standard for gastric biopsy more than 10 years ago [10].
According to this Classification, five biopsy sites should
be collected: one specimen each should be obtained
from the lesser and the greater curvature of the antrum,
both within 2–3 cm form the pylorus; from the lesser
curvature of the corpus about 4 cm proximal to the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ture of the corpus, approximately 8 cm from the cardia;
and one from incisura angularis. However, for the
consideration of patient’s comfort and operator’s con-
venience, this kind of extensive approach is uncommon
in our daily practice. Studies on the most practical
biopsy site for diagnosing H. pylori infection have con-
flicting results. Antrum biopsy is recommended by
Genta et al. [11] while others recommend at least one
corpus biopsy [12,13]. Hazell et al. and Woo et al. found
it necessary to take both antral and corpus biopsies
[14,15]. According to current guidelines, there is no
optimal site when performing a biopsy-based test in a
general condition, much less in those with gastritis with
atrophy [16].
It is suggested that as gastritis with atrophy pro-
gresses, the mid corpus is the last area involved and is
the last “lodgeable” mucosa for H. pylori in the stomach
[17,18]. Additional corpus biopsy is suggested in these
situations [12] but the exact additional benefit is not
well known.
This prospectively designed study used the combination
method as gold standard to investigate the correlation
among sensitivity of biopsy-based test, biopsy location,
degree of gastritis with atrophy, and H. pylori prevalence
rate.Methods
Patient population
Dyspeptic patients scheduled for upper gastrointestinal
endoscopy were recruited. Patients with any of the fol-
lowing conditions were excluded: (1) ulcer complications
(e.g., bleeding, stenosis, or perforation); (2) previous
stomach surgery; (3) gastric neoplasms; (4) use of any
substituted benzimidazoles and bismuth-containing pre-
parations within the last 7 days prior to the start of the
study; (5) past or current treatment with anti-H. pylori
therapy; or (6) severe systemic diseases. All patients pro-
vided prior informed consent and received invasive and
non-invasive tests for H. pylori. The local Ethics Com-
mittee on Human Test approved the study.Endoscopy and biopsy sampling
According to the updated Sydney system, the biopsy
sampling protocol required that more than five biopsy
samples were obtained: two from the antral mucosa; one
from the mucosa of the angularis incisura; two from the
oxyntic area. For the consideration of patients’ comfort
and operator’s convenience, we modified this recom-
mendation. Two biopsy sites with multiple biopsies were
applied to our endoscopy biopsy protocol. Three sets of
biopsy specimens each from the greater curvature of the
mid-body and lesser curvature of the antrum near theincisura were obtained during endoscopy for urease,
histologic, and culture tests.Rapid urease test
One biopsy from the greater curvature of the mid-body
and one from the lesser curvature near the incisura were
obtained for the urease test (CLO test; Delta West,
Bentley, Australia). Antral and body biopsy specimens
were evaluated separately, and the test was considered
positive when the color changed from orange to pink
within 24 hours.Histologic evaluation of the biopsy samples
Biopsy specimens from the antrum and the body were
fixed in formalin and assessed for the presence of
H. pylori by a modified Giemsa stain, and for the degree
of inflammatory cell infiltration, atrophy, and intestinal
metaplasia by hematoxylin and eosin staining. The
antrum and body histologic features of gastric mucosa
were graded according to the updated Sydney System
(0, none; 1, mild; 2, moderate; and 3, severe) [10]. In
addition, the degree of gastritis activity was evaluated in
Giemsa-negative patients with positive for either rapid
urease test or serology. Also, the activity of gastritis was
recorded according to the updated Sydney System. (1–4
points with 1 representing “normal”, 2 to 4 representing
“mildly, moderately and markedly active gastritis”,
respectively). Those who got two or more points on the
pathological review were regarded as active gastritis
which is an indirect sign of H. pylori infection. An
experienced pathologist (Anna Fen-Yau Li) who was
blinded to the results of other tests for H. pylori evalu-
ated all histologic sections.Culture
In culture, the biopsy sample was homogenized with 0.3
mL broth, plated on chocolate agar, and incubated at
37°C in a micro-aerobic (15% CO2 and 5% O2) incuba-
tor until the colony appeared, which was usually 3 days.
The negative plates were kept for 7 days. The growth of
H. pylori was confirmed by the characteristic morph-
ology (Gram-negative and curved) and positive catalase,
oxidase, and urease reactions observed.Serologic evaluation
Serum specimens were tested for the presence of IgG
antibodies against H. pylori using a quantitative ELISA
test (HEL-pTEST II; AMRAD, Kew, Australia) accord-
ing to the manufacturer’s instructions. A specimen was
considered positive if it contained >50 units/mL and
negative if it contained ≤50 units/mL.
Figure 1 Flow chart of the enrolled patients and the grouping
of biopsy specimens according to the degree of gastritis with
atrophy. H.P., Helicobacter pylori; NPV, negative predictive rate; PPV,
positive predictive rate.
Figure 2 Diagnostic tests for Helicobacter pylori detection:
Group A, definitely positive (n=103); Group B, probably positive
(n=1); Group C, probably negative (n=0); Group D, past H. pylori
infection or false positive (n=2); Group E, definitely negative (n=58);
CLO, indicates rapid urease test on biopsy specimens; Histology,
refers to H. pylori positive based on modified Giemsa staining;
Active gastritis, refers to presence or absence of active gastritis
(an indirect sign of active H. pylori infection).
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For serology studies, blood was drawn immediately after
endoscopy and collected and stored at −70°C until
assay. Fasting serum Pepsinogen I was measured in all
patients by radioimmunoassay (Pepsik; Sorin Biomedica,
Saluggia, Italy) according to the manufacturer’s instruc-
tions, while basal Pepsinogen II levels were determined
using a specific enzyme immunoassay (BIOHIT Plc,
Helsinki, Finland).
Gold standard definition
To define the gold standard of active H. pylori infection,
we modified the approach used by Shin et al. before [8]. A
patient was classified as current H. pylori infection based
on either a positive culture or, in the case of a negative
culture, both positive histology and positive urease test
(Group A). A patient was classified as H. pylori-negative
when the culture, histologic examination, urease test, and
serology were all negative (Group E). When either the
histologic examination (Giemsa stain or presence of
active gastritis) or urease test was positive, the results
were classified based on the results of serology test.
When IgG antibodies to H. pylori were detected, the
results were considered “probably positive” (Group B).
When IgG antibodies were not detected, the results
were regarded as being “probably negative” (Group C).
When a patient was serologically positive but negative
on all biopsy-based tests, this was interpreted as either a
past H. pylori infection or a false-positive result and the
patient was classified as negative for current H. pylori
infection (Group D). Groups A and B were defined as
gold standard positive while Groups C, D, and E were
gold standard negative.
Statistical analysis
Standard methods were used to calculate the sensitivity,
specificity, and positive and negative predictive values,
their 95% confidence intervals, and their test validity.
Chi-square tests were used to compare variables (i.e.,
number of cases who had moderate-to-marked gastritis
with atrophy at the antrum and corpus). To examine the
decreasing trend in the prevalence of histology, as influ-
enced by the severity of glandular atrophy, chi-square
test for trend was applied. All statistical analyses and
database collection were performed using the Statistical
Package for Social Sciences (SPSS 17.0 for Windows,
SPSS. Inc., Chicago, IL, USA).
Results
Subjects characteristics
A total of 164 patients were enrolled in this study. Regard-
less of the biopsy site, a total of 328 biopsy specimens
were received for histologic evaluation (Figure 1).Using the pre-defined gold standard, the results of the
four diagnostic tests for detecting current H. pylori
infection in all subjects (n=164) were shown in Figure 2.
Culture was positive in 87 patients. Among the patients
who were culture negative, 16 were positive for both
Table 1 Demographic characteristics of patients (n=164)










specimens and H. pylori status
Infection 208 (63.4)
Non infection 120 (36.6)
Peptic ulcer, no. (%)
GU 7 (4.2)
DU 53 (32.3)
Antrum gastritis with atrophy
Normal to mild 114 (69.5)
Moderate to severe 50 (31.5)
Body gastritis with atrophy
Normal to mild 141 (86.0)
Moderate to severe 23 (14.0)
Antrum intestinal metaplasia
Normal 145 (88.4)
Intestinal metaplasia 19 (11.6)
Body intestinal metaplasia
Normal 164 (100.0)
Intestinal metaplasia 0 (0)
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regarded as true positives (Group A). Moreover, one
patient was positive on serology and positive on either
the CLOtest or histology testing (Giemsa stain or pres-
ence of active gastritis), so this patient was classified as
probably H. pylori positive (Group B). No patient was
positive for a single biopsy-based test, so there was no
probably negative patient (Group C). Two patients were
positive on serology only (with titers of 67 unit/ml and
171 unit/ml, respectively). Their gastritis activity of the
biopsy specimens were reviewed again. None of them
showed active gastritis in the pathological review (both
of them got 1 point at their antrum and body biopsy
specimens). They were considered either a past H. pylori
infection or a false positive (Group D). Fifty-eight
patients were negative on all tests and were considered
true negative (Group E).
When Groups A and B were considered as H. pylori
positive and groups C, D, and E as H. pylori negative, the
patients’ characteristics, including numbers of H. pylori
infection, mean ratio of Pepsinogen I/II, and numbers of
peptic ulcer and gastritis with atrophy were shown in
Table 1. The overall H. pylori infection rate was 63.4% and
the mean Pepsinogen I/II ratio was 2.37. According to
Updated Sydney Classification, 50 patients (31.5%) had
moderate-to-severe antrum gastritis with atrophy, and
23 (14.0%) had moderate-to-severe body gastritis with
atrophy. Compared to the body, the antrum had signifi-
cantly higher percentage of gastritis with atrophy
(Figure 3). The antrum also had significantly higher per-
centage of intestinal metaplasia (antrum 11.6% vs. body
0%, p<0.001).
Sensitivity of biopsy based tests and degree of gastritis of
atrophy
Regardless of biopsy site, the biopsy specimens (n=328)
were grouped according to the degree of gastritis with
atrophy. Of these, 208 specimens were collected from
the “defined infection” patients (Groups A and B). In
these biopsy specimens, 101 had normal histology while
70 had mild, 34 had moderate, and 3 had severe gastritis
with atrophy. The sensitivity of histology Giemsa stain
and rapid urease test in these specimens were evaluated
(Figure 4) As the degree of gastritis with atrophy
progressed, the sensitivities of these two biopsy-based
test decreased (sensitivity of histology Giemsa stain in
normal, mild, moderate, and severe gastritis with atro-
phy was 100%, 100%, 88%, and 66%, respectively, while
the sensitivity of rapid urease test was 100%, 97%, 91%,
and 66%, respectively).
Sensitivity of biopsy based tests and biopsy sites
Using the pre-defined gold standard, the sensitivities
and specificities of the diagnostic tests, depending ongrade of antrum and body atrophy, were presented in
Tables 2 and 3. In moderate to severe antrum gastritis
with atrophy (n=50), single antrum biopsy for CLOtest
yielded fair sensitivity (84%; 95% CI: 63.08-94.75%),
which was lower than single body biopsy or combin-
ation of body and antrum (100%; 95% CI: 83.42-100%).
There was a similar finding in histology (sensitivity of
single antrum biopsy, 84% vs. 96% in single body biopsy
or combination of body and antrum). However, when
the degree of antrum gastritis with atrophy was normal-
to-mild, the sensitivity of both biopsy-based tests, re-
gardless of biopsy site, was between 97.47% and 100%
(Table 2).
In moderate-to-severe body gastritis with atrophy
(n=23), single antrum biopsy for CLOtest yielded fair
sensitivity (83.33%; 95% CI: 50.88-97.06%), which was
lower than single body biopsy or combination of body
and antrum (100%; 95% CI: 69.87-100%). A similar find-
ing was found in histology Giemsa stain (sensitivity of
Figure 3 The proportion of mild-severe and moderate-severe gastritis with atrophy based on biopsy site. The p value was calculated
using the chi-square test.
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biopsy or combination of body and antrum). However,
when the degree of body gastritis with atrophy was
normal to mild (n=141), the sensitivity of both biopsy
based tests, regardless of biopsy site, was between
95.66% and 100% (Table 3).
The prevalence rate of H. pylori infection between
normal, mild, moderate, and severe gastritis withFigure 4 The sensitivity of biopsy-based tests (histology Giemsa stainatrophy were evaluated. As the degree of gastritis with
atrophy increased, the prevalence rate of H. pylori infec-
tion decreased (Figure 5). As the degree of antrum gas-
tritis with atrophy increased, the prevalence rate of H.
pylori infection decreased significantly (p=0.027; chi-
square test for trends). A similar trend was found in
body gastritis with atrophy, with a trend of decreasing
H. pylori infection rate (p=0.216).and rapid urease test) according to grade of mucosal atrophy.
Table 2 H. pylori sensitivity and specificity depending on the grade of antrum gastritis with atrophy
Ca degree of gastritis with atrophy at antrum Normal to mild Moderate to severe
n=164 n=114 n=50
CLOtest Antrum
Sensitivity 97.47 (90.31-99.56) 84.00 (63.08-94.75)
Specificity 100.00 (87.68-100.00) 100.00 (83.42-100.00)
PPV 100.00 (94.08-100.00) 100.00 (80.76-100.00)
NPV 94.59 (80.47-99.06) 86.20 (67.43-95.49)
Accuracy 98.25
CLOtest Body
Sensitivity 100.00 (94.22-100.00) 100.00 (83.42-100.00)
Specificity 100.00 (87.68-100.00) 100.00 (83.42-100.00)
PPV 100.00 (94.22-100.00) 100.00 (83.42-100.00)
NPV 100.00 (87.68-100.00) 100.00 (83.42-100.00)
Accuracy 100.00 100.00
CLOtest Antrum + Body
Sensitivity 100.00 (94.22-100.00) 100.00 (83.42-100.00)
Specificity 100.00 (87.68-100.00) 100.00 (83.42-100.00)
PPV 100.00 (94.22-100.00) 100.00 (83.42-100.00)
NPV 100.00 (87.68-100.00) 100.00 (83.42-100.00)
Accuracy 100.00 100.00
Histology Antrum
Sensitivity 98.73 (92.18-99.93) 84.00 (63.08-94.75)
Specificity 100.00 (87.68-100.00) 100.00 (83.42-100.00)
PPV 100.00 (94.15-100.00) 100.00 (80.76-100.00)
NPV 97.22 (83.80-99.85) 86.20 (67.43-95.49)
Accuracy 99.12 92.00
Histology Body
Sensitivity 100.00 (94.22-100.00) 96.00 (77.68-99.79)
Specificity 100.00 (87.68-100.00) 100.00 (83.42-100.00)
PPV 100.00 (94.22-100.00) 100.00 (82.83-100.00)
NPV 100.00 (87.68-100.00) 96.15 (78.42-99.80)
Accuracy 100.00 98.00
Histology Antrum + Body
Sensitivity 100.00 (94.22-100.00) 96.00 (77.68-99.79)
Specificity 100.00 (87.68-100.00) 100.00 (83.42-100.00)
PPV 100.00 (94.22-100.00) 100.00 (82.83-100.00)
NPV 100.00 (87.68-100.00) 96.15 (78.42-99.80)
Accuracy 100.00 98.00
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Biopsy-based tests are important diagnostic tools for
H. pylori. However, the optimal biopsy site is still
unknown, especially in cases of gastritis with atrophy.
Current guidelines only recommend combining antrum
and body biopsies for rapid urease test in the circumstanceof antibiotics or proton pump inhibitors exposure. Sam-
pling from the angularis, corpus, and antrum for histology
was ever suggested in the same situation [16]. Reviewing
recent studies, there is little practical information about
the adequate biopsy numbers and suitable biopsy sites. Sin-
gle and multiple specimens at the antrum alone, at the
Table 3 H. pylori sensitivity and specificity depending on grade of body gastritis with atrophy
Ca degree of gastritis with atrophy at body Normal to mild Moderate to severe
n=164 n=141 n=23
CLOtest Antrum
Sensitivity 95.66 (88.62-98.60) 83.33 (50.88-97.06)
Specificity 100.00 (90.94-100.00) 100.00 (67.86-100.00)
PPV 100.00 (94.79-100.00) 100.00 (65.55-100.00)
NPV 92.45 (80.93-97.55) 84.61 (53.66-97.29)
Accuracy 97.16 91.30
CLOtest Body
Sensitivity 100.00 (95.00-100.00) 100.00 (69.87-100.00)
Specificity 100.00 (90.94-100.00) 100.00 (67.85-100.00)
PPV 100.00 (95.00-100.00) 100.00 (69.87-100.00)
NPV 100.00 (90.94-100.00) 100.00 (67.85-100.00)
Accuracy 100.00 100.00
CLOtest Antrum + Body
Sensitivity 100.00 (95.00-100.00) 100.00 (69.87-100.00)
Specificity 100.00 (90.94-100.00) 100.00 (67.85-100.00)
PPV 100.00 (95.00-100.00) 100.00 (69.87-100.00)
NPV 100.00 (90.94-100.00) 100.00 (67.85-100.00)
Accuracy 100.00 100.00
Histology Antrum
Sensitivity 96.74 (90.09-99.15) 83.33 (50.88-97.06)
Specificity 100.00 (90.94-100.00) 100.00 (67.86-100.00)
PPV 100.00 (94.84-100.00) 100.00 (65.55-100.00)
NPV 94.23 (83.08-98.50) 84.61 (53.66-97.29)
Accuracy 97.87 91.30
Histology Body
Sensitivity 100.00 (95.00-100.00) 91.67 (59.75-99.56)
Specificity 100.00 (90.94-100.00) 100.00 (67.86-100.00)
PPV 100.00 (95.00-100.00) 100.00 (67.86-100.00)
NPV 100.00 (90.94-100.00) 91.67 (59.75-99.56)
Accuracy 100.00 95.65
Histology Antrum + Body
Sensitivity 100.00 (95.00-100.00) 91.67 (59.75-99.56)
Specificity 100.00 (90.94-100.00) 100.00 (67.86-100.00)
PPV 100.00 (95.00-100.00) 100.00 (67.86-100.00)
NPV 100.00 (90.94-100.00) 91.67 (59.75-99.56)
Accuracy 100.00 95.65
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been described and applied (Table 4). These diagnostic
approaches seem largely arbitrarily [8,16,19-28]. In order
to clarify the exact benefit of these biopsy sites, a gold
standard is necessary.
In 2009, Shin et al. modified H. pylori diagnostic
methods and set a validated gold standard according tocombination tests results [8]. Since the combination
method is the preferred approach in patients with
gastritis with atrophy, the defined gold standard may
best correlate with active H. pylori infection. Our study
follows this approach to determine the best biopsy site
with highest sensitivity against a background of gastritis
with atrophy.
Figure 5 The prevalence rate of H. pylori infection according to
grade of antrum and body gastritis with atrophy. The p value
was calculated using the chi-square test for trend.
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biopsy at the antrum increases the risk of obtaining
atrophic gastric mucosa, which is associated higher
frequency of false negative results. Second, when body
gastritis with atrophy develops, antrum atrophy exists
already. Third, antrum biopsy alone has decreased
sensitivity when there is moderate-to-severe antrum
gastritis with atrophy (CLOtest up to 16% and histology
up to 12%) and moderate-to-severe body gastritis with
atrophy (CLOtest up to 16.67% and histology up to
8.34%).
First, the frequency of antrum gastritis with atrophy is
higher than that of the body. This is consistent with
previous studies [22,29]. It is believed that gastritis withTable 4 Studies on the diagnostic tests of H. pylori and the re







Choi et al. [22] Korea, health check-up
examinees
*1LA1LB 1LA
Hsu et al. [23] Taiwan, dyspepsia - 1LA
Vaira et al. [24] Italy, dyspepsia 2A 2A
Goh et al. [25] Malaysia, dyspepsia 1A1B 1A1
Shin et al. [8] Korea, gastritis with atrophy 2A2B 1A1
Siddique et al. [26] Kuwait, endoscopy evaluation - 1A
Yoo et al. [21] Korea, dyspepsia 2A2B 1LA
Yakoob et al. [27] Pakistan, dyspepsia 2A 2A
Kim et al. [28] Korea, gastric cancer 2LA2LB2GB 1GB




Chey et al. [15] Guideline 1GA1GB1Ag 1Ag
*1A, one piece from the antrum; 1B, one piece from the body; 2A2B, two pieces fro
of the antrum; 1LB, one piece from the lesser curvature of the body; 1GA, one piec
curvature of the body; 1AgB, one piece from the body angularis; 2U, two pieces froatrophy progresses from the antrum initially and
extends to the body in the advanced stage [12,17,18].
Thus, the prevalence rate of antrum gastritis with atro-
phy is significantly higher than that of the body. As
such, taking a biopsy at the antrum may yield higher
chances of atrophic gastric mucosa than taking one
from the body.
Regardless of biopsy site, if the degree of gastritis with
atrophy in each specimen is considered, sensitivity
decreases as the severity of gastritis with atrophy pro-
gresses (Figure 3). This is similar to the findings of Kim
et al. [22]. These false negative subjects could be proven
to be H. pylori infected after combining with other diag-
nostic methods. Such phenomenon is explained by the
increasing rate of sampling error as gastritis with atro-
phy progresses [29]. Thus, biopsy at antrum increases
the risk of getting atrophic gastric mucosa that is asso-
ciated with higher frequency of false negatives.
Second, applying the aforementioned conclusion on
biopsy site and on the degree of gastritis with atrophy, it
is interesting to find an opposite results between antrum
atrophy and body atrophy. Theoretically, biopsy site at
the atrophic area yields poorer sensitivity so single
antrum biopsy done in antrum atrophy subjects results
in less sensitivity. However, this principle does not apply
in single body biopsy performed in body atrophy cases.
Instead, the present study reveals a general rule that
antrum biopsy results in lower sensitivity in either
antrum or body atrophy. This is because when body
gastritis with atrophy occurs, antrum atrophy exists









Mean 47.8 515 53.2
vs. 1LA1GB Mean 55.0-57.8 355 33.5
Median 52 1000 45.3
B Mean 50.7 206 53.9
B Mean 57.7 651 41.2
vs. 2A vs. 3A vs. 4A Mean 36.1 100 -
1LB Mean 56.8 430 -
Mean 43 109 57.0
Median 61 194 84.0
Mean 63.5 324 53.7
Mean 10.4 254 -
B1GA - - -
m the antrum and 2 from the body; 1LA, one piece from the lesser curvature
e from the great curvature of the antrum;1GB, one piece from the great
m the ulcer margin.
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moderate-to-severe antrum atrophy (20/23).
Third, single body biopsy discloses an increased
sensitivity as compared with single antrum biopsy in a
background of moderate-to-severe antrum gastritis
with atrophy (CLOtest up to 16% and histology up to
12%). Similar finding is founded when corpus biopsy is
taken in moderate-to-severe body gastritis with atrophy
(with a increased sensitivity in CLOtest up to 16.67%
and histology up to 8.34%). In contrast, single antrum
and single corpus has comparable sensitivity when gastri-
tis with atrophy is normal-to-mild (CLOtest 97.47–95.66
and histology 96.74–98.73). Poor colonization of H. pylori
in the atrophic mucosa and intestinal metaplasia have
been well discussed [9,12]. When performing biopsy-
based test in a background of gastritis with atrophy,
sampling errors, insufficient bacterial load [9], bacterial
migration, bacterial clearance [12], bacterial patchy
distribution, and poor mucosal colonization in areas of
intestinal metaplasia are common causes of false negative
results. Furthermore, as the gastritis with atrophy pro-
gresses, the prevalence of H. pylori infection decreases.
Single specimen sampling at the antrum may miss this
relative small but risky patients. And this approach may
miss those who could get benefit from eradication.
Therefore, the present study recommends additional
corpus biopsy to avoid false negative results in moderate-
to-severe gastritis with atrophy.
This study has several potential limitations. First, it was
conducted in a H. pylori endemic area, such that the inter-
pretation and application of the study results should
consider the local H. pylori prevalence rate. Second, in
evaluating gastritis with atrophy by histology, the sampling
method used was based on the modified Updated Sydney
Classification. The latest approach method to evaluate
gastritis with atrophy is OLGA staging, which is com-
posed of multiple antrum and body biopsy specimens
[30]. The average grade of antrum and body gastritis with
atrophy in these specimens was evaluated while staging
was based on the degree and extent of gastritis with atro-
phy. In this study, only one piece at the antrum and one
at the body was used to represent the whole antrum and
body mucosal condition. This may be inadequate. How-
ever, compared to histology, non-invasive methods like
Pepsinogen I/II ratio also disclosed lower values
in moderate-to-severe gastritis with atrophy (mean
Pepsinogen I/II ratio, 1.96 in moderate-to-severe antrum
gastritis with atrophy and 1.79 in moderate-to-severe
body gastritis with atrophy). This may eliminate the
concern of inadequate sampling in the present study.
Third, though we used visual analogue scale to score the
gastritis with atrophy, grading of antrum atrophy is
most difficult for pathologists since kappa values are
very low and this wound be our limitation [10].Conclusion
Biopsy-based test should include corpus specimen in
cases of moderate-to-severe gastritis with atrophy to
avoid false negative results.
Abbreviations
H. pylori: Helicobacter pylori.
Competing interests
The authors have no potential conflicts (financial, professional, or personal).
Authors’ contributions
HC Lin, TS Chen and HC Lan designed the project. TS Chen, FY Chang and
AFY Lee performed the experiments. HC Lan wrote the manuscript. TS Chen
and HC Lan contributed to the discussion of the data and the revision of the
manuscript. All readers read and approved the final manuscript.
Authors’ information
Writing Assistance: Gene Alzona Nisperos, MD.
Acknowledgments
This study was supported by the Taiwan Otsuka Pharmaceutical Company
Ltd.
Author details
1Division of Gastroenterology, Department of Medicine, Taipei Veterans
General Hospital and National Yang-Ming University, #201 Shih-Pai Road,
Section 2, Taipei, Taiwan, ROC. 2Department of Pathology and Laboratory
Medicine, Taipei Veterans General Hospital and National Yang-Ming
University, Taipei, Taiwan, ROC. 3Division of General Medicine, Department of
Medicine, Taipei City Hospital, Taipei, Taiwan, ROC.
Received: 2 July 2012 Accepted: 13 December 2012
Published: 29 December 2012
References
1. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F,
Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ:
Management of Helicobacter pylori infection–the Maastricht IV/ Florence
Consensus Report. Gut 2012, 61:646–664.
2. Kuipers EJ, Uyterlinde AM, Pena AS, Roosendaal R, Pals G, Nelis GF, Festen
HP, Meuwissen SG: Long-term sequelae of Helicobacter pylori gastritis.
Lancet 1995, 345:1525–1528.
3. Ito M, Haruma K, Kamada T, Mihara M, Kim S, Kitadai Y, Sumii M, Tanaka S,
Yoshihara M, Chayama K: Helicobacter pylori eradication therapy improves
atrophic gastritis and intestinal metaplasia: a 5-year prospective study of
patients with atrophic gastritis. Aliment Pharmacol Ther 2002,
16:1449–1456.
4. Ohkusa T, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y, Yokoyama
T, Watanabe M: Improvement in atrophic gastritis and intestinal
metaplasia in patients in whom Helicobacter pylori was eradicated.
Ann Intern Med 2001, 134:380–386.
5. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G: The long-
term impact of Helicobacter pylori eradication on gastric histology: a
systematic review and meta-analysis. Helicobacter 2007, 12(Suppl2):32–38.
6. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D,
Hunt R, Rokkas T, Vakil N, Kuipers EJ: Current concepts in the management
of Helicobacter pylori infection: the Maastricht III Consensus Report.
Gut 2007, 56:772–781.
7. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A,
Graham DY, Tytgat G: Current concepts in the management of
Helicobacter pylori infection–the Maastricht 2-2000 Consensus Report.
Aliment Pharmacol Ther 2002, 16:167–180.
8. Shin CM, Kim N, Lee HS, Lee HE, Lee SH, Park YS, Hwang JH, Kim JW, Jeong
SH, Lee DH, Jung HC, Song IS: Validation of diagnostic tests for
Helicobacter pylori with regard to grade of atrophic gastritis and/or
intestinal metaplasia. Helicobacter 2009, 14:512–519.
9. Korstanje A, van Eeden S, Offerhaus GJ, Sabbe LJ, den Hartog G, Biemond I,
Lamers CB: The 13-carbon urea breath test for the diagnosis of
Lan et al. BMC Gastroenterology 2012, 12:182 Page 10 of 10
http://www.biomedcentral.com/1471-230X/12/182Helicobacter pylori infection in subjects with atrophic gastritis: evaluation
in a primary care setting. Aliment Pharmacol Ther 2006, 24:643–650.
10. Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of
gastritis. The updated Sydney system. International workshop on the
histopathology of gastritis, Houston 1994. Am J Surg Pathol 1996,
20:1161–1181.
11. Genta RM, Graham DY: Comparison of biopsy sites for the
histopathologic diagnosis of Helicobacter pylori: a topographic study of
H. pylori density and distribution. Gastrointest Endosc 1994, 40:342–345.
12. Satoh K, Kimura K, Taniguchi Y, Kihira K, Takimoto T, Saifuku K, Kawata H,
Tokumaru K, Kojima T, Seki M, Ido K, Fujioka T: Biopsy sites suitable for the
diagnosis of Helicobacter pylori infection and the assessment of the
extent of atrophic gastritis. Am J Gastroenterol 1998, 93:569–573.
13. Van IMC, Laheij RJ, de Boer WA, Jansen JB: The importance of corpus
biopsies for the determination of Helicobacter pylori infection. Neth J Med
2005, 63:141–145.
14. Hazell SL, Hennessy WB, Borody TJ, Carrick J, Ralston M, Brady L, Lee A:
Campylobacter pyloridis gastritis II: distribution of bacteria and associated
inflammation in the gastro-duodenal environment. Am J Gastroenterol
1987, 82:297–301.
15. Woo JS, El-Zimaity HM, Genta RM, Yousfi MM, Graham DY: The best gastric
site for obtaining a positive rapid urease test. Helicobacter 1996,
1:256–259.
16. Chey WD, Wong BC: American college of gastroenterology guideline on
the management of helicobacter pylori infection. Am J Gastroenterol 2007,
102:1808–1825.
17. Correa P: Chronic gastritis: a clinico-pathological classification. Am J
Gastroenterol 1988, 83:504–509.
18. Kimura K: Chronological transition of the fundic-pyloric border
determined by step-wise biopsy of the lesser and greater curvatures of
the stomach. Gastroenterology 1972, 63:584–592.
19. Choi J, Kim CH, Kim D, Chung SJ, Song JH, Kang JM, Yang JI, Park MJ, Kim
YS, Yim JY, Lim SH, Kim JS, Jung HC, Song IS: Prospective evaluation of a
new stool antigen test for the detection of Helicobacter pylori, in
comparison with histology, rapid urease test, (13)C-urea breath test, and
serology. J Gastroenterol Hepatol 2011, 26:1053–1059.
20. Goh KL, Cheah PL, Navaratnam P, Chin SC, Xiao SD: HUITAI rapid urease
test: a new ultra-rapid biopsy urease test for the diagnosis of
Helicobacter pylori infection. J Dig Dis 2007, 8:139–142.
21. Hsu WH, Wang SS, Kuo CH, Chen CY, Chang CW, Hu HM, Wang JY, Yang YC,
Lin YC, Wang WM, Wu DC, Wu MT, Kuo FC: Dual specimens increase the
diagnostic accuracy and reduce the reaction duration of rapid urease
test. World J Gastroenterol 2010, 16(23):2926–2930.
22. Kim CG, Choi IJ, Lee JY, Cho SJ, Nam BH, Kook MC, Hong EK, Kim YW:
Biopsy site for detecting Helicobacter pylori infection in patients with
gastric cancer. J Gastroenterol Hepatol 2009, 24:469–474.
23. Roma-Giannikou E, Roubani A, Sgouras DN, Panayiotou J, Van-Vliet C,
Polyzos A, Roka K, Daikos G: Endoscopic tests for the diagnosis of
helicobacter pylori infection in children: validation of rapid urease test.
Helicobacter 2010, 15:227–232.
24. Siddique I, Al-Mekhaizeem K, Alateeqi N, Memon A, Hasan F:
Diagnosis of Helicobacter pylori improving the sensitivity of CLOtest
by increasing the number of gastric antral biopsies: J Clin
Gastroenterol 2008, 42:356–360.
25. Tang JH, Liu NJ, Cheng HT, Lee CS, Chu YY, Sung KF, Lin CH, Tsou YK, Lien
JM, Cheng CL: Endoscopic diagnosis of Helicobacter pylori infection by
rapid urease test in bleeding peptic ulcers: a prospective case–control
study. J Clin Gastroenterol 2009, 43:133–139.
26. Vaira D, Vakil N, Gatta L, Ricci C, Perna F, Saracino I, Fiorini G, Holton J:
Accuracy of a new ultrafast rapid urease test to diagnose Helicobacter
pylori infection in 1000 consecutive dyspeptic patients. Aliment
Pharmacol Ther 2010, 31:331–338.
27. Yakoob J, Jafri W, Abid S, Jafri N, Abbas Z, Hamid S, Islam M, Anis K, Shah
HA, Shaikh H: Role of rapid urease test and histopathology in the
diagnosis of Helicobacter pylori infection in a developing country.
BMC Gastroenterol 2005, 5:38.
28. Yoo JY, Kim N, Park YS, Hwang JH, Kim JW, Jeong SH, Lee HS, Choe C, Lee
DH, Jung HC, Song IS: Detection rate of Helicobacter pylori against a
background of atrophic gastritis and/or intestinal metaplasia. J Clin
Gastroenterol 2007, 41:751–755.29. Kang HY, Kim N, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Jung HC,
Song IS: Progression of atrophic gastritis and intestinal metaplasia drives
Helicobacter pylori out of the gastric mucosa. Dig Dis Sci 2006,
51:2310–2315.
30. Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G, Graham
DY: Gastritis staging in clinical practice: the OLGA staging system.
Gut 2007, 56:631–636.
doi:10.1186/1471-230X-12-182
Cite this article as: Lan et al.: Additional corpus biopsy enhances the
detection of Helicobacter pylori infection in a background of gastritis
with atrophy. BMC Gastroenterology 2012 12:182.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
